Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

9.14
+0.06000.66%
Post-market: 9.250.1100+1.20%19:30 EDT
Volume:338.52K
Turnover:3.09M
Market Cap:731.10M
PE:-1.56
High:9.36
Open:9.10
Low:8.80
Close:9.08
52wk High:14.87
52wk Low:7.00
Shares:79.99M
Float Shares:35.75M
Volume Ratio:1.14
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8439
EPS(LYR):-4.3039
ROE:-81.92%
ROA:-47.10%
PB:2.26
PE(LYR):-2.12

Loading ...

Company Profile

Company Name:
BridgeBio Oncology Therapeutics, Inc
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
88
Office Location:
256 East Grand Avenue,Suite 104,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
BridgeBio Oncology Therapeutics, Inc. was incorporated on June 15, 2021, as a Cayman Islands exempted company. Effective August 12, 2025, the company completed a previously announced business combination and is now domiciled in Delaware. BBOT is a clinical-stage biotechnology company whose mission is to transform the lives of cancer patients driven by two of the most commonly mutated oncogenes: RAS and PI3Kα.

Directors

Name
Position
Eli Wallace
Chief Executive Officer and Director
Frank P. McCormick
Director and Chairman of the board
Bihua Chen
Director
Jake Bauer
Director
Michelle Doig
Director
Neil Kumar
Director
Praveen Tipirneni
Director
Raymond Kelleher
Director

Shareholders

Name
Position
Eli Wallace
Chief Executive Officer and Director
Uneek Mehra
Chief Financial Officer
Pedro J. Beltran
Chief Scientific Officer
Yong Ben
Chief Medical and Development Officer